Summary

Paresthesia Treatment Market – Scope of Report
TMR’s report on the global paresthesia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paresthesia treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paresthesia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the paresthesia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paresthesia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paresthesia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paresthesia treatment market.

The report delves into the competitive landscape of the global paresthesia treatment market. Key players operating in the global paresthesia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paresthesia treatment market profiled in this report.

Key Questions Answered in Global paresthesia treatment Market Report
• What is the sales/revenue generated by paresthesia treatment across all regions during the forecast period?
• What are the opportunities in the global paresthesia treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Paresthesia Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global paresthesia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global paresthesia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paresthesia treatment market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paresthesia Treatment Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Paresthesia Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Paresthesia Treatment Market Analysis and Forecast, by Type
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Type, 2020-2034
        6.3.1. Acute Paresthesia
        6.3.2. Chronic Paresthesia
    6.4. Market Attractiveness, by Type
7. Global Paresthesia Treatment Market Analysis and Forecast, by Treatment
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Treatment, 2020-2034
        7.3.1. Immunosuppressants
        7.3.2. Anticonvulsants
        7.3.3. Topical Creams
        7.3.4. Antivirals
    7.4. Market Attractiveness, by Treatment
8. Global Paresthesia Treatment Market Analysis and Forecast, by Indication
    8.1. Introduction and Definitions
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Indication, 2020-2034
        8.3.1. Radiculopathy
        8.3.2. Neuropathy
    8.4. Market Attractiveness, by Indication
9. Global Paresthesia Treatment Market Analysis and Forecast, by End-user
    9.1. Introduction and Definitions
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2020-2034
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness, by End-user
10. Global Paresthesia Treatment Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2020-2034
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness, by Region
11. North America Paresthesia Treatment Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Type, 2020-2034
        11.2.1. Acute Paresthesia
        11.2.2. Chronic Paresthesia
    11.3. Market Attractiveness, by Type
    11.4. Market Value Forecast, by Treatment, 2020-2034
        11.4.1. Immunosuppressants
        11.4.2. Anticonvulsants
        11.4.3. Topical Creams
        11.4.4. Antivirals
    11.5. Market Attractiveness, by Treatment
    11.6. Market Value Forecast, by Indication, 2020-2034
        11.6.1. Radiculopathy
        11.6.2. Neuropathy
    11.7. Market Attractiveness, by Indication
    11.8. Market Value Forecast, by End-user, 2020-2034
        11.8.1. Hospital Pharmacies
        11.8.2. Retail Pharmacies
        11.8.3. Online Pharmacies
    11.9. Market Attractiveness, by End-user
    11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.10.1. U.S.
        11.10.2. Canada
    11.11. Market Attractiveness Analysis
        11.11.1. By Type
        11.11.2. By Treatment
        11.11.3. By Indication
        11.11.4. By End-user
        11.11.5. By Country
12. Europe Paresthesia Treatment Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Type, 2020-2034
        12.2.1. Acute Paresthesia
        12.2.2. Chronic Paresthesia
    12.3. Market Attractiveness, by Type
    12.4. Market Value Forecast, by Treatment, 2020-2034
        12.4.1. Immunosuppressants
        12.4.2. Anticonvulsants
        12.4.3. Topical Creams
        12.4.4. Antivirals
    12.5. Market Attractiveness, by Treatment
    12.6. Market Value Forecast, by Indication, 2020-2034
        12.6.1. Radiculopathy
        12.6.2. Neuropathy
    12.7. Market Attractiveness, by Indication
    12.8. Market Value Forecast, by End-user, 2020-2034
        12.8.1. Hospital Pharmacies
        12.8.2. Retail Pharmacies
        12.8.3. Online Pharmacies
    12.9. Market Attractiveness, by End-user
    12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.10.1. Germany
        12.10.2. U.K.
        12.10.3. France
        12.10.4. Italy
        12.10.5. Spain
        12.10.6. Rest of Europe
    12.11. Market Attractiveness Analysis
        12.11.1. By Type
        12.11.2. By Treatment
        12.11.3. By Indication
        12.11.4. By End-user
        12.11.5. By Country/Sub-region
13. Asia Pacific Paresthesia Treatment Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Type, 2020-2034
        13.2.1. Acute Paresthesia
        13.2.2. Chronic Paresthesia
    13.3. Market Attractiveness, by Type
    13.4. Market Value Forecast, by Treatment, 2020-2034
        13.4.1. Immunosuppressants
        13.4.2. Anticonvulsants
        13.4.3. Topical Creams
        13.4.4. Antivirals
    13.5. Market Attractiveness, by Treatment
    13.6. Market Value Forecast, by Indication, 2020-2034
        13.6.1. Radiculopathy
        13.6.2. Neuropathy
    13.7. Market Attractiveness, by Indication
    13.8. Market Value Forecast, by End-user, 2020-2034
        13.8.1. Hospital Pharmacies
        13.8.2. Retail Pharmacies
        13.8.3. Online Pharmacies
    13.9. Market Attractiveness, by End-user
    13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.10.1. China
        13.10.2. Japan
        13.10.3. India
        13.10.4. Australia & New Zealand
        13.10.5. Rest of Asia Pacific
    13.11. Market Attractiveness Analysis
        13.11.1. By Type
        13.11.2. By Treatment
        13.11.3. By Indication
        13.11.4. By End-user
        13.11.5. By Country/Sub-region
14. Latin America Paresthesia Treatment Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Type, 2020-2034
        14.2.1. Acute Paresthesia
        14.2.2. Chronic Paresthesia
    14.3. Market Attractiveness, by Type
    14.4. Market Value Forecast, by Treatment, 2020-2034
        14.4.1. Immunosuppressants
        14.4.2. Anticonvulsants
        14.4.3. Topical Creams
        14.4.4. Antivirals
    14.5. Market Attractiveness, by Treatment
    14.6. Market Value Forecast, by Indication, 2020-2034
        14.6.1. Radiculopathy
        14.6.2. Neuropathy
    14.7. Market Attractiveness, by Indication
    14.8. Market Value Forecast, by End-user, 2020-2034
        14.8.1. Hospital Pharmacies
        14.8.2. Retail Pharmacies
        14.8.3. Online Pharmacies
    14.9. Market Attractiveness, by End-user
    14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.10.1. Brazil
        14.10.2. Mexico
        14.10.3. Rest of Latin America
    14.11. Market Attractiveness Analysis
        14.11.1. By Type
        14.11.2. By Treatment
        14.11.3. By Indication
        14.11.4. By End-user
        14.11.5. By Country/Sub-region
15. Middle East & Africa Paresthesia Treatment Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Type, 2020-2034
        15.2.1. Acute Paresthesia
        15.2.2. Chronic Paresthesia
    15.3. Market Attractiveness, by Type
    15.4. Market Value Forecast, by Treatment, 2020-2034
        15.4.1. Immunosuppressants
        15.4.2. Anticonvulsants
        15.4.3. Topical Creams
        15.4.4. Antivirals
    15.5. Market Attractiveness, by Treatment
    15.6. Market Value Forecast, by Indication, 2020-2034
        15.6.1. Radiculopathy
        15.6.2. Neuropathy
    15.7. Market Attractiveness, by Indication
    15.8. Market Value Forecast, by End-user, 2020-2034
        15.8.1. Hospital Pharmacies
        15.8.2. Retail Pharmacies
        15.8.3. Online Pharmacies
    15.9. Market Attractiveness, by End-user
    15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
        15.10.1. GCC Countries
        15.10.2. South Africa
        15.10.3. Rest of Middle East & Africa
    15.11. Market Attractiveness Analysis
        15.11.1. By Type
        15.11.2. By Treatment
        15.11.3. By Indication
        15.11.4. By End-user
        15.11.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2023)
    16.3. Company Profiles
        16.3.1. Pfizer Inc.
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Novartis AG
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. GSK PLC
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Merck & Co., Inc.
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Johnson & Johnson
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Teva Pharmaceutical Industries Ltd.
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. AbbVie Inc.
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Amgen Inc.
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. AstraZeneca plc
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Bayer AG
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Eli Lilly & Co.
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
        16.3.12. Sanofi S.A.
            16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.12.2. Product Portfolio
            16.3.12.3. Financial Overview
            16.3.12.4. SWOT Analysis
            16.3.12.5. Strategic Overview